Drug Repurposing in Parkinson’s Disease

Foltynie, Thomas

doi:10.1007/s40263-018-0548-y

Cited by 40 publications

(30 citation statements)

References 163 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…EX-4 has been found to exert powerful neuroprotective properties in several other experimental neurodegenerative disease model systems including PD and Alzheimer’s disease (for review see Athauda and Foltynie, 2016a,b; Athauda and Foltynie, 2018), Huntington’s disease (Martin et al, 2009), amyotrophic lateral sclerosis and stroke (Hölscher, 2014) and other neuroinflammatory diseases (multiple sclerosis: Lee et al, 2018). However, the mechanism(s) by which EX-4 and other GLP1-R agonists exert these effects is still unclear.…”

Section: Discussionmentioning

confidence: 99%

Structural Changes Observed in the Piriform Cortex in a Rat Model of Pre-motor Parkinson’s Disease

Sancandi

Schul

Economides

et al. 2018

Front. Cell. Neurosci.

View full text Add to dashboard Cite

Early diagnosis of Parkinson’s disease (PD) offers perhaps, the most promising route to a successful clinical intervention, and the use of an animal model exhibiting symptoms comparable to those observed in PD patients in the early stage of the disease, may facilitate screening of novel therapies for delaying the onset of more debilitating motor and behavioral abnormalities. In this study, a rat model of pre-motor PD was used to study the etiology of hyposmia, a non-motor symptom linked to the early stage of the disease when the motor symptoms have yet to be experienced. The study focussed on determining the effect of a partial reduction of both dopamine and noradrenaline levels on the olfactory cortex. Neuroinflammation and striking structural changes were observed in the model. These changes were prevented by treatment with a neuroprotective drug, a glucagon-like peptide-1 (GLP1) receptor agonist, exendin-4 (EX-4).

show abstract

Section: Discussionmentioning

confidence: 99%

Structural Changes Observed in the Piriform Cortex in a Rat Model of Pre-motor Parkinson’s Disease

Sancandi

Schul

Economides

et al. 2018

Front. Cell. Neurosci.

View full text Add to dashboard Cite

show abstract

“…Previous studies highlighted the importance of drug repurposing studies for certain types of diseases including, Parkinson's, Alzheimer's and Ebola [10] , [11] , [12] , [13] , [14] . Virtual screening research would replace the time-consuming efforts in identification of new targets for the existing drug molecules as demonstrated in earlier articles [15] , [16] , [17] .…”

Section: Introductionmentioning

confidence: 99%

Fenoterol and dobutamine as SARS-CoV-2 main protease inhibitors: A virtual screening study

Bolelli

Ertan-Bolelli

Ünsalan

et al. 2021

Journal of Molecular Structure

View full text Add to dashboard Cite

Highlights Fenoterol and dobutamine inhibit COVID-19 main protease (6W63). Docking study showed that fenoterol docked better than dobutamine. Fenoterol and dobutamine may be used in treatment of COVID-19. These compounds were extracted from ZINC database against COVID-19. Virtual screening approach helped to find two FDA approved drugs.

show abstract

“…Drug repurposing is regarded as a way to discover new applications of the existing drugs in treating various diseases [1]. This technique may speed up the process of finding the therapeutic compounds for the newly emerged illnesses [2][3][4][5][6]. Signature matching, which is based on detecting the unique signatures of drugs, is one of the computational approaches to be used.…”

Section: Introductionmentioning

confidence: 99%

A multimodal deep learning-based drug repurposing approach for treatment of COVID-19

et al. 2020

View full text Add to dashboard Cite

Recently, various computational methods have been proposed to find new therapeutic applications of the existing drugs. The Multimodal Restricted Boltzmann Machine approach (MM-RBM), which has the capability to connect the information about the multiple modalities, can be applied to the problem of drug repurposing. The present study utilized MM-RBM to combine two types of data, including the chemical structures data of small molecules and differentially expressed genes as well as small molecules perturbations. In the proposed method, two separate RBMs were applied to find out the features and the specific probability distribution of each datum (modality). Besides, RBM was used to integrate the discovered features, resulting in the identification of the probability distribution of the combined data. The results demonstrated the significance of the clusters acquired by our model. These clusters were used to discover the medicines which were remarkably similar to the proposed medications to treat COVID-19. Moreover, the chemical structures of some small molecules as well as dysregulated genes' effect led us to suggest using these molecules to treat COVID-19. The results also showed that the proposed method might prove useful in detecting the highly promising remedies for COVID-19 with minimum side effects. All the source codes are accessible using https ://githu b.com/LBBSo ft/Multi modal-Drug-Repur posin g.git

show abstract

Drug Repurposing in Parkinson’s Disease

Cited by 40 publications

References 163 publications

Structural Changes Observed in the Piriform Cortex in a Rat Model of Pre-motor Parkinson’s Disease

Structural Changes Observed in the Piriform Cortex in a Rat Model of Pre-motor Parkinson’s Disease

Fenoterol and dobutamine as SARS-CoV-2 main protease inhibitors: A virtual screening study

A multimodal deep learning-based drug repurposing approach for treatment of COVID-19

Contact Info

Product

Resources

About